Resources and insights to help you keep up with policy and market trends in a transforming healthcare ecosystem

Showing In the Press

ADVI Director Lindsay Bealor Greenleaf talks to Bloomberg Law

Greenleaf weighs in on the Trump Administration’s proposed rule on drug rebates and how the role they play will be both more transparent and defined.

Read more

ADVI director, Becca Davison, spoke with Morning Consult about defining value for pharmaceuticals and which factors are important to include in the process

Becca Davison, director at health care advisory company ADVI Health and former director at the Pharmaceutical Research and Manufacturers of America, said some of the more rote, formulaic ways that have been used to place “value” on drugs in the past have failed to take into account metrics that are important to society, such as quality of life and the overall effect on the health care system.

Read more

ADVI Director, Lindsay Bealor Greenleaf, talked with CNBC about the Administration’s proposed rule on rebates and what it could mean for drug prices and PBMs

“The market consolidation that we’ve seen with pharmacy benefits managers makes it harder for manufacturers to push back against this demand for rebates” explained Lindsay Bealor Greenleaf, a director at ADVI Health, a health care policy consultancy.

Read more

Director Lindsay Bealor Greenleaf discussed concerns regarding Medicare Part B step therapy with FierceHealthcare

Another wrinkle in the policy that’s confusing to providers is the policy’s reward system, Lindsay Bealor Greenleaf, director of ADVI Health, told FierceHealthcare. Insurers can offer rewards such as gift cards to patients on lower-cost alternatives, but they’re not making the choice themselves to take on a cheaper drug, she said.

Read more